Cost-Effectiveness Analysis of Branded Drugs With Market Demand and Insurance.
Cost-Effectiveness Analysis of Branded Drugs With Market Demand and Insurance.
复制标题
品牌药与市场需求和保险的成本效益分析。
DOI：
10.1016/j.jval.2021.04.1289
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Martinez,JosephR
中科院分区：
文献类型：
--
作者：
Pauly,MarkV;Comanor,WilliamS;Frech3rd,HE;Martinez,JosephR
ObjectivesCost-effectiveness analysis of branded pharmaceuticals presumes that both cost (or price) and marginal effectiveness levels are exogenous. This assumption underlies most judgments of the cost-effectiveness of specific drugs. In this study, we show the theoretical implications of letting both factors be endogenous by modeling pharmaceutical price setting with and without health insurance, along with patient response to the prices that depend on marginal effectiveness. We then explore the implications of these models for cost-effectiveness ratios.MethodsWe used simple textbook models of patient demand and pricing behavior of drug firms to predict market equilibria in the drug and insurance markets and to generate calculations of the cost-effectiveness ratios in those settings.ResultsWe found that ratios in market settings can be much different from those calculated in cost-effectiveness studies based on exogenous prices and treatment of all patients at risk rather than those who would demand treatment in a market setting. We also found that there may be considerable similarity in these market cost-effectiveness ratios across different products because drug firms with market power set profit-maximizing prices.ConclusionsWe found that market cost-effectiveness ratios will always indicate an excess of benefits over cost. Insurance will lead to less favorable ratios than without insurance, but when insurers bargain with drug firms, rather than taking their prices as given, cost-effectiveness ratios will be more favorable.
